RxDoctor Payments Data

Howard Lewis, MD

Cardiovascular Disease · Seattle, WANPI 1518041235

Payments from drug & device makers

$151in general payments, 2019–2025

Across 5 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$66
  • Boston Scientific$26
  • Johnson & Johnson$25
  • Edwards Lifesciences$22
  • Ironshore Pharmaceuticals Inc.$12

What the payments were for

  • Food & beverage$151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$151 in reported general payments places this provider in the 20th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$274,239
Medicare patients
1,741
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban625$901,485
XareltoRivaroxaban263$352,719
Repatha SureclickEvolocumab63$74,105
EntrestoSacubitril/Valsartan62$66,841
BrilintaTicagrelor37$28,869
JardianceEmpagliflozin26$28,392
Praluent PenAlirocumab30$26,765
Dabigatran EtexilateDabigatran Etexilate Mesylate37$10,576
Atorvastatin Calcium816$8,480
Metoprolol Succinate614$8,344
Rosuvastatin Calcium442$5,150
Losartan Potassium416$5,023
Ezetimibe243$4,288
ClopidogrelClopidogrel Bisulfate332$3,277
Carvedilol353$3,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$352,719263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →